Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

280.37 +0.36 (+0.13%)
Streaming Delayed Price Updated: 2:07 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
47 48 Next >
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday
Via Benzinga
Wall Street Looks To Feed Off Apple's Post-Earnings Power But Key Jobs Data May Upset The Cart: Analyst Says 'A Lot Of These Clouds Will Lift' If This Happens
Stocks look set to carry forward the upward momentum on Friday amid some earnings cheer, although a tinge of nervousness is evident ahead of the all-important non-farm payrolls report. 
Via Benzinga
Why Apple Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Amgen's Options: A Look at What the Big Money is Thinking
Via Benzinga
Amgen Stock Adds Good Weight After CEO's Update On Experimental Drug Rivaling Ozempic, Nixing Oral Weight-Loss Candidate
MariTide, formerly AMG 133, is an injectable form of drug targeting two gut hormones — gastric inhibitory polypeptide receptor, or GIP, and glucagon-like peptide 1, or GLP-1. 
Via Benzinga
Apple, Coinbase, Block, Amgen, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Thursday saw major U.S. indices closing on a positive note, with the Dow Jones Industrial Average climbing 0.85% to reach 38,225.66 
Via Benzinga
Topics Stocks
Exposures US Equities
AMGN Stock Earnings: Amgen Beats EPS, Beats Revenue for Q1 2024
AMGN stock results show that Amgen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Amgen reported quarterly earnings of $3.96 per share which beat the analyst consensus estimate of $3.87 by 2.33%. The company said EPS decreased by 1% due to higher operating and interest expenses... 
Via Benzinga
Amgen Beats First-Quarter Expectations, But Shares Slide As Investors Watch Obesity Space
The company confirmed it's still running a midstage study of its obesity drug, MariTide. 
Via Investor's Business Daily
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Amgen?
Via Benzinga
Wall Street Inches Up After Powell's Inflation Remarks; Chipmakers Rebound; Gold, Crude Falter: What's Driving Markets Thursday?
U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can
Uncover the vulnerabilities of these Dow stocks to sell, with potential declines due to cash flow issues, pricing pressures and flat sales. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
American stocks were mixed on Wednesday as the earnings season continued and as investors waited for the latest Federal Reserve decision. The Dow Jones rose by over 65 points while the S&P 500 and... 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With CytomX Stock?
CytomX Therapeutics shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8, after the close of... 
Via Benzinga
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Sandoz resolves patent litigation with Amgen, paving the way for the launch of denosumab biosimilars Jubbonti and Wyost. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Explore the use of Amgen's Blincyto in treating severe systemic sclerosis, shedding light on Cullinan Therapeutics' CLN-978 potential for autoimmune diseases, particularly systemic lupus... 
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
These two pharma stocks have followed distinct paths of late. Which is the better investment? 
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
This Vanguard growth fund is home to some of the world's most innovative companies. 
Via The Motley Fool
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
Explore opportunities in the cable, restaurant and biotechnology sectors, revealing how dividend growth stocks are maximizing returns. 
Via InvestorPlace
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... 
Via Benzinga
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
When it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue. 
Via InvestorPlace
Exposures Product Safety
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
Though stocks that make the Dow 30 are often seen as solid investments, investors should consider these three blue chip stocks to sell. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Amgen's shares have come under pressure this year, making it a compelling bargain buy. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Not every business in operation today is built to thrive -- or even last -- indefinitely. These are. 
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Investors can find some of the hottest, most explosive opportunities in these three top biotech stocks to buy now. 
Via InvestorPlace
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Amgen, Canadian Solar, and Diana Shipping are three undervalued stocks with high potential for growth that can enhance portfolio returns. 
Via InvestorPlace
Amgen, Shell And More On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Amy Raskin of Chevy Chase Trust said Shell plc (NYSE: SHEL) has 12% free 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
47 48 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.